🚀 go-pugleaf

Cancer – Press Review  – Revue de Presse

Every week on http://marclacroixcancerblog.blogspot.com
Chaque semaine sur http://marclacroixcancerblog.blogspot.com




Press review  (November 12, 2011) – Revue de presse (12 novembre 2011)


Cancer treatment shows promise for rapid weight loss
A synthetic peptide that inhibits blood supply, a strategy employed in
many cancer drugs, is found to kill fat cells and improve metabolic
function in trials involving monkeys.
By Melissa Healy. In Los Angeles Times
http://www.latimes.com/health/la-he-drug-fat-loss-20111110,0,5914182.story

'Epigenetic' therapy shows promise for hard-to-treat lung cancer
A new 'epigenetic' therapy appears to be able to prolong the life of
patients with late-stage non-small cell lung cancer (NSCLC), according
to the results of a small clinical trial published in the journal
Cancer Discovery.
In Cancer Research UK
http://info.cancerresearchuk.org/news/archive/cancernews/2011-11-10-Epigenetic-therapy-shows-promise-for-hard-to-treat-lung-cancer

Computer 'pathologist' could assess breast cancer survival
A new computer model analyzes microscopic breast cancer images and
predicts patient survival better than the pathologists who do the job
now, new research suggests.
By Kathleen Doheny. USA Today
http://yourlife.usatoday.com/health/medical/breastcancer/story/2011-11-10/Computer-pathologist-could-assess-breast-cancer-survival/51151756/1

Roche skin cancer drug to get priority review in U.S
Roche's experimental skin cancer drug vismodegib has been given
"priority review" status by U.S. authorities, the Swiss drugmaker said
on Wednesday.
Reuters
http://www.reuters.com/article/2011/11/09/us-roche-idUSTRE7A81Z920111109

More Evidence That HPV Vaccine Shields Against Cervical Cancer
Coverage against precancerous lesion called 'excellent' in large,
multinational study.
In U.S. News & World Report
http://health.usnews.com/health-news/family-health/cancer/articles/2011/11/09/more-evidence-that-hpv-vaccine-shields-against-cervical-cancer

Bavarian Nordic's Immunotherapy Product Candidate CV-301 Shows Promise
in Breast and Ovarian Cancer
Bavarian Nordic A/S (OMX: BAVA) today announced that encouraging
clinical trial results with CV-301 in patients with metastatic breast
or ovarian cancer were published in Clinical Cancer Research, a peer-
reviewed journal of the American Association for Cancer Research.
Through an expanded collaboration with the National Cancer Institute
(NCI) and license with the National Institutes of Health (NIH), the
Company obtained rights to CV-301, an off-the-shelf cancer
immunotherapy product candidate for multiple cancers, in October
2011.
Reuters
http://www.reuters.com/article/2011/11/08/idUS217784+08-Nov-2011+HUG20111108

Screening For Several Cancer-Causing Genetic Mutations
For the first time, investigators in the U.S. have demonstrated that
it is possible to screen individuals with cancer for a variety of
cancer-causing genetic mutations as part of normal clinical practice.
Doctors have the ability to target tumors with the most suitable
treatment by identifying patients' individual genotypes within a
fairly short time period.
By Grace Rattue. In Medical News Today
http://www.medicalnewstoday.com/articles/237460.php

UK cost body rules against AstraZeneca cancer drug
AstraZeneca's breast cancer drug Faslodex has been rejected for use on
Britain's state health service, dealing a blow to a product that has
been on the market in Europe since 2004.
Reuters
http://www.reuters.com/article/2011/11/10/astrazeneca-britain-idUSL6E7M95JA20111110

UT MD Anderson study finds acupuncture can prevent radiation-induced
chronic dry mouth
When given alongside radiation therapy for head and neck cancer,
acupuncture has shown for the first time to reduce the debilitating
side effect of xerostomia, according to new research from The
University of Texas MD Anderson Cancer Center and Fudan University
Shanghai Cancer Center.
In EurekAlert
http://www.eurekalert.org/pub_releases/2011-11/uotm-uma111011.php

Cancer : les perturbateurs endocriniens sur la sellette
L'Académie de médecine reconnaît la nocivité probable du bisphénol A
ou des parabènes mais juge «irréalisable» leur interdiction tant que
la fiabilité des produits de remplacement n'a pas été prouvée. Par
Marc Mennessier. Dans Le Figaro
http://sante.lefigaro.fr/actualite/2011/11/09/15768-cancer-perturbateurs-endocriniens-sur-sellette

Cancer du sein: augmentation des ablations mammaires sauf chez les
50-74 ans
Le taux de mastectomies totales, ou ablation d'un sein pour traiter un
cancer, a tendance à augmenter depuis 2005, excepté parmi les femmes
de 50 à 74 ans, selon une étude présentée mercredi à Marseille au
congrès de la Société de sénologie.
AFP
http://www.leparisien.fr/marseille-13000/cancer-du-sein-augmentation-des-ablations-mammaires-sauf-chez-les-50-74-ans-09-11-2011-1711905.php

Adopter la moustache contre le cancer de la prostate‎‎
Lancée comme une blague en 2004, la campagne de prévention «Movember»
rencontre un succès grandissant dans le monde anglo-saxon.
Par Cyrille Vanlerberghe. Dans Le Figaro
http://sante.lefigaro.fr/actualite/2011/11/08/15756-adopter-moustache-contre-cancer-prostate


La thérapie épigénétique testée dans le cancer du poumon
La thérapie épigénétique a donné des résultats prometteurs chez
quelques patients ayant un cancer du poumon métastasé réfractaire :
elle a allongé la survie moyenne et des réponses remarquables ont été
observées chez une petite fraction des patients.
Le Quotidien du Médecin
http://www.lequotidiendumedecin.fr/information/la-therapie-epigenetique-testee-dans-le-cancer-du-poumon

Cancer de la peau: procédure d'homologation accélérée au Etats-Unis
pour un médicament
L'autorité américaine des médicaments (FDA) a accordé au médicament
Vismodegib, destiné à traiter certaines formes de cancer de la peau,
une procédure d'homologation accélérée, a indiqué mercredi le groupe
pharmaceutique suisse Roche.
AFP
http://www.google.com/hostednews/afp/article/ALeqM5iEW7EPg0BOHMkfjiLZHgI9ys17wA?docId=CNG.ad509228f5f2cc812ff9949c697de07d.471










Cancer Blog – Marc Lacroix – Le Blogue du Cancer
http://marclacroixcancerblog.blogspot.com










Marc Lacroix – InTextoResearch – Baelen  (11/2011)